Global antibiotic manufacturer Target institutions and distributors seeking parenteral cephalosporin antibiotics for US and international markets; emphasize Steri-Pharma’s cost-effective, high-quality production and reliability as a differentiator.

Growth and expansion Identify growth opportunities tied to Steri-Pharma’s planned $50M plant expansion and headcount growth, presenting partnerships or contract manufacturing options to scale production capacity and meet rising demand.

Talent driven Leverage the company’s people-centric culture and strong benefits to position as a stable, long-term manufacturing partner; highlight potential for collaborative R&D or process improvement programs with a focus on human antibiotics.

Regional advantage Syracuse location with downtown access and cost-effective operations can be marketed to regional distributors and US-based customers seeking nearshore or reliable domestic manufacturing for regulatory and supply chain resilience.

Financial and incentives Capitalize on tax incentives and grants associated with the expansion; propose financing-friendly manufacturing partnerships or contract manufacturing arrangements that align with Steri-Pharma’s growth phase and revenue scale.